1 / 16

This study was funded by Amgen Inc.

Panitumumab Efficacy and Patient-Reported Outcomes in Metastatic Colorectal Cancer Patients With Wild-Type KRAS Tumor Status.

bud
Download Presentation

This study was funded by Amgen Inc.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Panitumumab Efficacy and Patient-Reported Outcomes in Metastatic ColorectalCancer Patients With Wild-Type KRAS Tumor Status Rafael G. Amado, MD;1 Michael Wolf, MS;1 Dan Freeman, PhD;1Marc Peeters, MD, PhD;2 Eric Van Cutsem, MD, PhD;3Salvatore Siena, MD;4 Sid Suggs, PhD;1 Giovanna Devercelli, PhD;1Michael Woolley, PhD;1 and David Chang, PhD1 1Amgen Inc., Thousand Oaks, CA, USA; 2Ghent University Hospital, Ghent, Belgium;3University Hospital Gasthuisberg, Leuven, Belgium; 4Ospedale Niguarda Ca’Granda, Milan, Italy This study was funded by Amgen Inc.

  2. Disclosures • This study was sponsored by Amgen Inc. • R.G. Amado, M. Wolf, D. Freeman, S. Suggs, S. Patterson, D. Chang, T. Juan, M. Reiner, and R. Radinsky are Amgen employees and own Amgen Inc. stock. • M. Peeters, Amgen advisory board and Amgen honoraria; E. Van Cutsem, Amgen advisory board and Amgen honoraria; N.J. Meropol, consultant for Amgen, Genentech, and Imclone; J. Berlin, advisory boards for Amgen, BMS, and Imclone.

  3. Introduction • Panitumumab, a fully human monoclonal antibody directed against EGFr, has demonstrated efficacy as monotherapy in patients with metastatic colorectal cancer (mCRC).1, 2 • Recent studies have suggested that the mutational status of the KRAS gene in tumors of patients with mCRC may impact response to anti-EGFr therapies.3 • A phase 3, randomized controlled trial demonstrated that panitumumab was well tolerated and significantly improved progression-free survival compared with best supportive care alone, in refractory mCRC patients.2 • Using tumor samples from that study,we correlated KRAS status with clinical and patient-reported outcomes. 1 Vectibix™ Prescribing Information; Amgen Inc. Thousand Oaks CA, 2007 2 Van Cutsem E, et al. J Clin Oncol 2007;25:1658–1664. 3 Benvenuti S, et al. Cancer Res. 2007;67:2643–2648.

  4. R A N D O M I Z E Panitumumab PD Follow-up 6.0 mg/kg Q2W + BSC BSC PD Follow-up Optional Panitumumab Crossover Study KRAS Analysis of a Phase 3, Randomized, Controlled Trial Comparing Panitumumab vs BSC in Colorectal Cancer Hypothesis: There would be a larger treatment effect in patients with wild-type KRAS compared to patients with mutant KRAS 1:1 • Randomization stratification • ECOG score (0-1 vs. 2) • Geographic region (Western EU vs. Central & Eastern EU vs. Rest of World) Van Cutsem E et al. J Clin Oncol 2007;25:1658–1664.

  5. Objectives and Analysis Methodology Primary Objective • To assess whether the effect of panitumumab on PFS was significantly greater in patients with wild-type KRAS compared with mutant KRAS Secondary Objectives • To assess whether panitumumab improves PFS compared with BSC alone in patients with wild-type KRAS • To assess whether panitumumab improves overall survival (OS) compared with BSC alone in patients with wild-type KRAS Test for a PFS effect among all randomized patients at a 5% level Test for quantitative PFS effect interaction, i.e., wild-type effect > mutant p ≤ 0.05 p > 0.05 Compare PFS in wild-type KRAS subset STOP p ≤ 0.05 p > 0.05 Compare OR & OS in wild-type KRAS subset STOP

  6. DNA was isolated from fixed tumor samples Mutant KRAS was detected using a KRAS mutation kit (DxS Ltd, Manchester, UK) that used allele-specific, real-time PCR The kit can detect approximately 1% of mutant DNA in a background of wild-type genomic DNA The test identifies 7 somatic mutations in codons 12 and 13 Gly 12 Asp Gly 12 Ala Gly 12 Val Gly 12 Ser Assay Used to Detect KRAS Mutational Status • Gly 12 Arg • Gly 12 Cys • Gly 13 Asp

  7. Patient Disposition Screened N = 1,040 Randomized N = 463 Randomized to BSC alone N = 232 Randomized to panitumumab + BSC N = 231 Excluded from KRAS analyses (missing or unevaluable) N = 36 KRAS mutant N = 84 KRAS mutant N = 100 WT KRAS N = 124 WT KRAS N = 119 Received P’mab in X-over protocol N = 77 Received P’mab in X-over protocol N = 90 r p r t o l n = 9 0 BSC = Best supportive care; WT = wild-type

  8. M e d ian M ean M e d ian M ean 1 . 0 0 1 1 . . 0 0 ( W ks) E v e n t s /N ( % ) ( W ks) ( W ks) E v e n t s /N ( % ) ( W ks) 0 . 9 9 0 0 . . 9 9 P P m m ab ab + + BS BS C C 76/84 76/84 ( ( 90) 90) 7.4 7.4 9.9 9.9 P m ab + BS C 115/124 ( 93) 12.3 19.0 0 . 8 8 10.2 10.2 BS BS C C A A l l one one 95/100 95/100 ( ( 95) 95) 7.3 7.3 0 0 . . 8 8 9.3 BS C A l one 114/119 ( 96) 7.3 0 . 7 7 0 0 . . 7 7 HR = 0.99 (95% CI: 0.73–1.36) HR = 0.45 (95% CI: 0.34–0.59) 0 . 6 6 0 0 . . 6 6 Proportion Event-free S t r at i f i ed l og - r a n k te s t , p < 0.00 0 1 0 . 5 5 0 0 . . 5 5 0 . 4 4 0 0 . . 4 4 0 . 3 3 0 0 . . 3 3 0 . 2 2 0 0 . . 2 2 0 . 1 1 0 0 . . 1 1 0 . 0 0 0 0 . . 0 0 0 2 4 6 8 10 12 14 16 18 2 0 2 2 2 4 2 6 2 8 3 0 3 2 3 4 3 6 3 8 4 0 4 2 4 4 4 6 4 8 5 0 5 2 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52 W eek s W eek s P P a a t t i i e e n n t t s s a a t t R R i i s s k k P P m m a a b b + + B B SC SC 8 4 8 4 7 7 8 8 7 7 6 6 7 7 6 2 2 1 2 2 0 6 1 8 0 6 8 5 6 5 5 5 5 5 5 4 5 4 4 4 4 4 4 2 4 2 2 2 2 2 2 2 2 2 2 2 2 1 2 1 1 1 1 1 12 4 11 9 11 2 10 6 8 0 6 9 6 3 5 8 5 0 4 5 4 4 4 4 3 3 2 5 2 1 2 0 1 7 1 3 1 3 1 3 1 0 7 7 6 5 5 10 0 10 9 1 0 7 9 7 1 6 7 1 7 3 6 7 1 2 3 2 7 2 1 2 9 1 1 0 9 1 9 0 8 9 6 8 5 6 5 5 4 5 4 4 4 4 4 4 4 4 4 4 3 4 3 3 3 3 2 3 2 2 2 2 2 2 2 11 9 10 9 9 1 8 1 3 8 2 0 1 5 1 5 1 4 1 1 1 0 9 9 6 6 6 6 5 4 3 3 2 2 2 2 1 B B S S C C A A l l on on e e PFS by KRAS Status and Treatment Mutant KRAS WT KRAS • The relative effect of panitumumab versus BSC was significantly greater in patients with WT versus mutant KRAS. • The quantitative-interaction test comparing the magnitude of the relative treatment effect on PFS between WT and mutant KRAS was statistically significant (p < 0.0001). • PFS was significantly greater for panitumumab treatment compared with BSC in the WT KRAS group (stratified log-rank test p < 0.0001).

  9. P P m m ab ab + + BS BS C C BS BS C C A A l l one one PFS – Interval Censored (Sensitivity Analysis) by KRAS Status and Treatment Mutant KRAS WT KRAS M e d ian M e d ian E v e n t s /N ( % ) ( W ks) E v e n t s /N ( % ) ( W ks) 76/84 ( 90) 8 115/124 ( 93) 16 95/100 ( 95) 8 114/119 ( 96) 8 HR=0.49 (95% CI: 0.37-0.65) HR=1.07 (95% CI: 0.77-1.48) Weeks Weeks

  10. Mutant Wild-Type 160 160 140 140 PR (0%) SD (12%) PD (70%) PR (17%) SD (34%) PD (36%) 120 120 100 100 80 80 60 60 Pmab + BSC % Change % Change 40 40 20 20 0 0 -20 -20 -40 -40 -60 -60 -80 -80 Patient Patient 160 160 140 140 PR (0%) SD (8%) PD (60%) PR (0%) SD (12%) PD (75%) 120 120 100 100 80 80 60 60 BSC Alone 40 40 % Change % Change 20 20 0 0 -20 -20 -40 -40 -60 -60 -80 -80 Patient Patient Maximum Percent Decrease in Target Lesions Final Analysis, KRAS Evaluable Group BSC = Best supportive care; Pmab = panitumumab

  11. Overall Survival by KRAS Status and Treatment Median In Months Events / N (%) 1.0 Pmab, Wild-type 107 / 124 (86) 8.1 0.9 BSC, Wild-type 110 / 119 (92) 7.6 0.8 Pmab, Mutant 79 / 84 (94) 4.9 0.7 BSC, Mutant 95 / 100 (95) 4.4 0.6 Survival Probability Wild-type vs. Mutant (treatment arms combined) 0.5 0.4 HR = 0.67 (95% CI: 0.55–0.82) adjusted for treatment and randomization factors (ECOG, region) 0.3 0.2 0.1 0.0 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 Months Pmab WT, N 124 92 58 35 18 9 3 2 1 BSC WT, N 119 82 54 28 18 10 5 1 0 Pmab Mutant, N 84 51 21 10 6 3 3 1 0 BSC Mutant, N 100 55 30 18 11 3 0 0 0

  12. Treatment Difference (95% CI) for FACT/NCCN Colorectal Cancer Symptom Index (FCSI) Mutant KRAS WT KRAS Imputed - LVCF Panitumumab - BCS Imputed - LVCF Panitumumab - BCS 20.00 20.00 16.00 16.00 12.00 12.00 8.00 8.00 4.00 4.00 FCSI Difference 0.00 0.00 -4.00 -4.00 -8.00 -8.00 -12.00 -12.00 -16.00 -16.00 4 8 12 16 4 8 12 16 Week Week MCID= -4.0

  13. 14.00 14.00 12.00 12.00 10.00 10.00 8.00 8.00 6.00 6.00 4.00 4.00 2.00 2.00 0.00 0.00 EORTC Global Health -2.00 -2.00 -4.00 -4.00 -6.00 -6.00 -8.00 -8.00 -10.00 -10.00 -12.00 -12.00 -14.00 -14.00 -16.00 -16.00 4 8 12 16 4 8 12 16 Week Treatment Difference (95% CI) for EORTC-QLQ-C30 Global Health Status Mutant KRAS WT KRAS Imputed - LVCF Panitumumab - BCS Imputed - LVCF Panitumumab - BCS Week MCID = -7.07

  14. Median (Wks) Events / N (%) Median (Wks) Events / N (%) 52 / 54 (96) 7.6 18 / 18 (100) 7.4 84 / 90 (93) 22.4 ≤ 66.667 1.0 ≤ 66.667 > 66.667 18 / 18 (100) 7.4 > 66.667 0.9 0.8 0.7 0.6 Proportion Event-Free 0.5 0.4 0.3 0.2 0.1 0 10 20 30 40 50 60 70 80 90 100 0.0 Weeks from Randomization Weeks from Randomization 0 10 20 30 40 50 60 70 80 90 PFS by Minimum Post-Baseline mDLQI Score, Panitumumab Landmark Safety Seta Mutant KRAS WT KRAS aExcludes patients with progression-free survival < 28 days. By mDLQI scores, dichotomization of PFS for degree of being bothered was explored using all possible cut points of mDLQI (based on the effect size from a Cox model) to find the maximum difference by mDLQI score.

  15. Conclusions • In patients with chemotherapy-refractory mCRC, the clinical efficacy of panitumumab monotherapy appears to be restricted to patients with WT KRAS tumors • Results of QOL analyses by KRAS status are consistent with clinical outcomes • KRAS genotyping of tumors should be strongly considered in patients with mCRC being treated with panitumumab monotherapy • Ongoing studies in 1st and 2nd lines will prospectively examine the effect of panitumumab in combination with chemotherapy in patients with WT and mutant KRAS tumors

  16. Acknowledgments • We thank the patients and their families for study participation, investigators and study personnel

More Related